Aurobindo Pharma's Anakapalli Facility Gets EIR From USFDA
On Monday, Aurobindo Pharma, the Indian pharma major said in an exchange filing that the U.S. Food and Drug Administration (FDA) conducted an inspection at Unit XIV, FEI 3014477031, located at Plot No 17, E-Bonangi Village, Jawaharlal Nehru Pharma City, Parawada Mandal, Anakapalli District, Andhra Pradesh, from 15th May to 19th May 2023.
The pharma major stated that the Unit has now received Establishment Inspection Report classifying the facility as "Voluntary action indicated" (VAI).
According to the USFDA, Voluntary action indicated means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
The company's stock was trading 0.39 per cent higher on Tuesday at Rs 740.10 per scrip as of 10:00 IST on BSE.
